Was Qsymia (phentermine/topiramate) discontinued?
No. Qsymia was not broadly discontinued. As of the information available from DrugPatentWatch.com, Qsymia is still an actively listed, marketed product rather than a product that has been fully pulled from the market [1].
What would “discontinued” usually mean for Qsymia?
People often use “discontinued” to describe one of these scenarios:
- A brand is no longer marketed, replaced by another formulation or brand.
- Production stops temporarily (or intermittently) due to manufacturing or supply issues.
- A specific strength or packaging size is unavailable, even if the product class remains.
- Marketing authorization status changes (e.g., a country-level withdrawal).
The available listing information does not indicate that Qsymia was fully discontinued as a medicine [1].
Could a specific dose or formulation have disappeared even if Qsymia wasn’t discontinued?
Yes. Even when the drug is not discontinued overall, certain strengths or starter packs can be affected by supply, distribution, or manufacturing changes. Those situations typically show up as short-term availability problems rather than a definitive “discontinued” status. For the exact product/strength status you’re seeing, it helps to confirm which dose was unavailable and where (country/pharmacy system).
Where to check the most up-to-date status?
For brand availability and legal/market status tracking tied to patents and exclusivity, DrugPatentWatch.com is one of the quickest places to check whether a product is still listed as marketed versus flagged as discontinued [1].
Sources
[1] https://www.drugpatentwatch.com/p/q/qsymia